Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blumenthal to lead U.S. health IT expansion

Executive Summary

HHS names David Blumenthal, most recently director of the Institute for Health Policy at the Massachusetts General Hospital/Partners Health Care System in Boston, as the national coordinator for health information technology. In this role, Blumenthal is tasked with implementing a nationwide health IT infrastructure, a daunting task based on results of small-scale rollouts (1"The Pink Sheet," March 2, 2009, p. 36). Blumenthal was a senior health advisor to President Obama during the campaign; he also has ties to Sen. Ted Kennedy, D-Mass., as a staffer on the Subcommittee on Health and Scientific Research in the 1970s. Blumenthal appeared on a preliminary list of candidates for FDA commissioner, but it was expected that he would land somewhere else within the administration (2"The Pink Sheet," Nov. 3, 2008, p. 25)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel